Yousuf Zafar, MD, will advise The Samfund on research and evaluation of data to enhance its ability to combat financial aftereffects of cancer treatment.
The Samfund has announced the addition of Yousuf Zafar, MD, associate professor of medicine and public policy, and a gastrointestinal oncologist at the Duke Cancer Institute, to its advisory council. Zafar will advise The Samfund on research and evaluation of data to enhance its ability to combat financial aftereffects of cancer treatment.
Costs associated with cancer treatment can be a significant burden in a young adult cancer survivor’s life. Research conducted by The Samfund has found that the average net worth of a young adult cancer survivor receiving grants from the organization is approximately -$35,000, compared with $68,000 for young adults in the general population.
“While cancer treatment is evolving and improving, innovation comes at a high price,” Zafar said. "Every day, patients are making sacrifices to afford their cancer care. Not only do patients worry about the physical toxicity of cancer treatment, but they also have to worry about financial toxicity. I’m honored to be a part of The Samfund’s mission to reduce the financial toxicity experienced by cancer survivors and to ensure expenses do not stand between a patient and the best possible treatment.”
Communication gaps were also highlighted in the research that came out of The Samfund’s research study. Many young adults faced issues with initiating a conversation around finances with their doctors; they were ashamed or reluctant to start any financial conversation with their care provider. In his own research studies, Zafar has identified this disconnect—51% of cancer patients included in the study wanted to discuss cost considerations with their doctors, but only 19% actually do.
Samantha Watson, founder and CEO of The Samfund, said, “With Dr Zafar advising us on promoting adherence to medical treatment and new approaches to financial toxicity, we are better poised to help young adult survivors avoid it in the first place. We hear stories every day from individuals who are forgoing follow-up exams with their doctors, dental and mental health care, and facing hard choices between paying medical bills and their grocery bills.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More